1935 ⎘
Rearing or breeding animals, not otherwise provided for; New breeds of animals; New breeds of vertebrates; Genetically modified vertebrates, e.g. transgenic Knockout animals
COMPOSITIONS AND METHODS FOR THE STUDY AND TREATMENT OF ACUTE KIDNEY INJURY
#302Ungulates with genetically modified immune systems
#303Anti-tumor properties of Dickkopf 3b
#304Humanized non-human animals with restricted immunoglobulin heavy chain loci
#305A METHOD FOR REGULATING THE FUNCTION OF A HEART CELL, RELATED NUCLEOTIDES AND COMPOUNDS
#306Genetically engineered non-human mammal, construction method therefor and use thereof
#307Humanized low affinity FCγR mouse cells
#308NSG mice lacking MHC class I and class II
#309Genetically modified non-human animals expressing human EPO
#310Method of preparing ddx27-deletion zebrafish mutants
#311METHODS FOR IDENTIFYING MBLAC1-DEPENDENT MOLECULAR NETWORKS
#312ACTIVITY MODULATOR, MEDICINAL AGENT COMPRISING SAME, USE OF CD300A GENE-DEFICIENT MOUSE, AND ANTI-CD300A ANTIBODY
#313METHODS FOR INCREASING THE DIVERSITY OF MONOCLONAL ANTIBODIES PRODUCED AGAINST AN ANTIGEN
#314Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof
#315ENGINEERING OF HUMANIZED CAR T-CELL AND PLATELETS BY GENETIC COMPLEMENTATION
#316Non-meiotic allele introgression
#317Transgenic mice with inducible neuron-specific inactivation of HuR gene and method of screening
#318Fumarylacetoacetate hydrolase (FAH)-deficient and immunodeficient rats and uses thereof
#319EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA)
#320Late-onset Alzheimer's disease animal model and uses thereof
#321Genetically modified non-human animal with human or chimeric OX40
#322Genetically modified non-human animal with human or chimeric CTLA-4
#323Method of using a genetically modified mouse that expresses a humanized CTLA-4 gene
#324Preventive or therapeutic agent for kidney disease
#325Production method for conditional knockout animal
#326Method of constructing zebrafish mutants
#327Genetically modified non-human animal with human or chimeric OX40
#328Genetically modified mouse comprising a chimeric TIGIT
#329Gene therapy for haploinsufficiency
#330Parkinson's disease model and methods
#331ANIMAL MODEL FOR DRUG DEVELOPMENT
#332Multiplexed genome editing
#333Application of GPR45 gene
#334RODENT MODELS WITH AUTISTIC FEATURES
#335Genetically modified non-human animal with human or chimeric CD28
#336GENETICALLY STERILE ANIMALS
#337Method of inactivating a FEL D1 gene using crispr
#338Genetically modified non-human animal with human or chimeric TIGIT
#339REGENERATION METHOD USING SOMATIC CELL NUCLEAR TRANSFER (SCNT) CELL AND BLASTOCYST COMPLEMENTATION
#340Targeted modification of rat genome
#341Non-human animals having a humanized lymphocyte-activation gene 3
#342Immunodeficient non-human animal
#343TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
#344Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV)
#345MRAP2 KNOCKOUTS
#346Repressors of viral infection
#347Mouse Models Having a Knockin Scavenger Receptor Class B Type I
#348COMPOSITIONS AND METHODS UTILIZING LYSOPHOSPHATIDYLCHOLINE SCAFFOLDS
#349Cancer Treatment and Immune System Regulation Through FAT10 Pathway Inhibition
#350GPCR (GPR113) INVOLVED IN FAT, FATTY ACID AND/OR LIPID-ASSOCIATED TASTE AND USE IN ASSAYS FOR IDENTIFYING TASTE MODULATORY
#351Genetically modified non-human animals and methods for producing heavy chain-only antibodies
#352NON-HUMAN ANIMAL EXHIBITING DIMINISHED UPPER AND LOWER MOTOR NEURON FUNCTION AND SENSORY PERCEPTION
#353TIE2 RECEPTOR ACTIVATION FOR GLAUCOMA
#354Engineering of Humanized Kidney by Genetic Complementation
#355Construction Method for Immunodeficient Rat Model
#356Animal model of brain tumor and manufacturing method of animal model
#357Biomarkers and label-free nucleic acid biomarker detection in cancer and other diseases
#358METHOD FOR ESTABLISHING A NON-HUMAN MAMMALIAN ANIMAL MODEL SUFFERING FROM OBESITY OR RELATED DISEASE AND USE THEREOF
#359Genetically Edited Animal
#360Non-human animals having a disruption in a C9ORF72 locus
#361Animal model of Angelman Syndrome
#362Methods and compositions for treating chronic granulomatous disease
#363Humanized non-human animals with restricted immunoglobulin heavy chain loci
#364Compositions and methods for treating and preventing metabolic disorders
#365Use of C1q/TNF-related protein-1 (CTRP1) to treat fatty liver disease
#366Atopic dermatitis model non-human animal and use thereof
#367METHODS AND COMPOSITIONS RELATING TO IMPROVED HUMAN RED BLOOD CELL SURVIVAL IN GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMALS
#368ANIMAL MODELS FOR POLYCYSTIC KIDNEY DISEASE
#369Method of using a transgenic mouse with alpha-one antitrypsin (ATT) deficiency to screen compounds
#370COMPOSITIONS AND METHODS FOR INHIBITING ENDOGENOUS IMMUNOGLOBULIN GENES AND PRODUCING TRANSGENIC HUMAN IDIOTYPE ANTIBODIES
#371Human liver chimeric mouse with deficient P450 oxidoreductase
#372Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith
#373METHOD AND DEVICE FOR DRUG SCREENING
#374Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
#375VE-PTP KNOCKOUT
#376Compositions and methods for modulating neuronal excitability and motor behavior
#377GENERATION OF GENETICALLY ENGINEERED ANIMALS BY CRISPR/CAS9 GENOME EDITING IN SPERMATOGONIAL STEM CELLS
#378ORGAN REGENERATION METHOD UTILIZING iPS CELL AND BLASTOCYST COMPLEMENTATION
#379Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
#380Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
#381Humanized dipeptidyl-peptidase IV (DPP4) animals
#382Anti-Ryk antibodies and methods of using the same
#383HUMAN CTLA-4 ANTIBODIES AND THEIR USES
#384Methods of treating mitochondrial disorders
#385EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA)
#386Methods and compositions for the targeted modification of a mouse ES cell genome
#387ACTIVATION OF TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND CRITICAL ROLE FOR TRPV4 IN ORGAN-SPECIFIC INFLAMMATION AND ITCH
#388Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase
#389Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
#390METHOD OF PRODUCING INFERTILE FISH AND EGG-PRODUCING AQUATIC ANIMALS AND OF DELIVERING COMPOUNDS INTO EGGS AND EMBRYOS
#391ANIMAL MODEL FOR STUDYING ZCCHC6 IN BONE DISEASE AND DEVELOPMENT
#392Transgenic cloned piglet expressing human proinsulin and method of producing the same
#393Pathogen-resistant animals having modified CD163 genes
#394Medical use of CREG protein
#395GENETIC MODIFICATION NON-HUMAN ORGANISM, EGG CELLS, FERTILIZED EGGS, AND METHOD FOR MODIFYING TARGET GENES
#396METHOD FOR IDENTIFYING BIOACTIVE PROTEIN, AND BIOACTIVE PROTEIN OBTAINED BY SAID METHOD
#397Compositions and methods for genetically modifying myosin phosphatase target subunit (Mypt1) gene for lowering blood pressure
#398Common light chain mouse
#399LDL receptor gene knockout, genetically-engineered hamster
#400TRANSGENIC MICE
#401Inhibitors of α-tubulin acetylation for the treatment of pain
#402Transgenic pig which simultaneously expresses HO-1 gene and TNFR1-Fc gene, and comprises knocked-out GGTA1 gene, and use thereof
#403MYO1A for predicting conversion of acute pain into chronic pain and use of MYO1A for therapy of pain
#404Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
#405Treatment of heart disease by inhibtion of the action of muscle A-kinase anchoring protein (mAKAP)
#406Regulation of mesodermal specification
#407Porcine reproductive and respiratory syndrome virus resistant animals
#408TRPV1 KNOCK-IN METHOD AND TRPV1 MICE FOR ADIPOSE TISSUE MODULATION
#409Mutations in rhodopsin gene in zebrafish and uses thereof
#410Methods of treating muscular dystrophy
#411Porcine animals lacking expression of functional alpha 1, 3 galactosyltransferase
#412ANIMAL MODELS FOR BRAIN INFLAMMATION AND WHITE MATTER DEGENERATION
#413COMPOSITIONS AND METHODS RELATING TO TUMOR ANALYSIS
#414Methods of treating or preventing pruritis by blocking natriuretic polypeptide b
#415Leg1 Protein, Leg1 Gene, and Uses and Drugs thereof
#416Transgenic Animals
#417Genetically modified rat models for severe combined immunodeficiency (SCID)
#418Method of producing infertile fish and egg-producing aquatic animals and of delivering compounds into eggs and embryos
#419Multiplexed genome editing
#420Method for measuring tumor burden in patient derived xenograft (PDX) mice
#421METHOD FOR PREPARING A CANINE MODEL OF ATHEROSCLEROSIS
#422Methods and compositions for treatment of atherosclerosis
#423Generation and correction of a humanized mouse model with a deletion of dystrophin exon 44
#424Motor neuron-specific expression vectors
#425Method of inactivating the IPK1 gene in corn
#426Method of making trabecular bone
#427Non-human animal models of retinoschisis
#428Methods and compositions for targeted genetic modifications and methods of use
#429Androgenetic haploid embryonic stem cell (AG-HAESC), and preparation method and use thereof
#430Methods of increasing T cell immune response in the treatment of cancer
#431Immunity enhancing agent for cancer by Allergin-1 antagonist
#432Compositions and methods for treating bone diseases
#433MULTIPLEX GENE EDITING
#434METHOD OF STEM CELL-BASED ORGAN AND TISSUE GENERATION
#435INHIBITING CTRP5 ACTION TO IMPROVE INSULIN RESISTANCE ASSOCIATED WITH OBESITY AND TYPE 2 DIABETES
#436DNA editing using relatively long single-stranded DNA and CRISPR/Cas9 to increase success rate in methods for preparing transgenic embryos and animals
#437Humanized skeletal muscle
#438Humanized heart muscle
#439Micro-RNA family that modulates extracellular matrix genes and uses thereof
#440AUF1 ENCODING COMPOSITIONS FOR MUSCLE CELL UPTAKE, SATELLITE CELL POPULATIONS, AND SATELLITE CELL MEDIATED MUSCLE GENERATION
#441Siglec transgenic mice and methods of use thereof
#442Double knockout (GT/CMAH-KO) pigs, organs and tissues
#443TRANSGENIC ANIMAL MODELS FOR CYSTIC FIBROSIS
#444Treatment methods using DNA editing with single-stranded DNA
#445Method for producing non-human large mammal or fish each capable of producing gamete originated from different individual
#446TAFA4 COMPOUNDS AND USES THEREOF FOR TREATING PAIN
#447Disease model pig exhibiting stable phenotype, and production method thereof
#448Genetic modification of pigs for xenotransplantation
#449METHODS OF CHARACTERIZING E-SYT2 INHIBITORS, E-SYT2 INHIBITORS, AND METHODS OF USE
#450Transgenic chicken comprising an inactivated immunoglobulin gene
#451Method of treating vitiligo using mutant HSP70i
#452Mouse with D4R iRNA in the intercalating cell mass of the amygdala
#453Gene editing of reproductive hormones to sterilize aquatic animals
#454Genetically modified non-human animals and methods of use thereof
#455Genetically modified pig cells with an inactivated Etv2 gene
#456Identification of a 5-Gene Expression Signature Predicting Clinical Outcome of Patients with Brain Tumors
#457Porcine reproductive and respiratory syndrome virus resistant animals
#458ACTIVATION OF TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND CRITICAL ROLE FOR TRPV4 IN ORGAN-SPECIFIC INFLAMMATION AND ITCH
#459Gene knockout method
#460Humanized FcγR mice
#461Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
#462B4GALNT2 knock out pig
#463Modulation and detection of a neuronal alternative splicing regulatory network for treatment and diagnosis of neurological disorders
#464P21-activated kinase inhibitor domain targeted transgenic mouse
#465TIE2 RECEPTOR ACTIVATION FOR GLAUCOMA
#466TRIPLE TRANSGENIC PIGS SUITABLE FOR XENOGRAFT
#467Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
#468SIGNATURES AND PCDETERMINANTS ASSOCIATED WITH PROSTATE CANCER AND METHODS OF USE THEREOF
#469Methods and compositions for generating a mouse
#470Parkinsons disease model and methods
#471Cancer treatment and immune system regulation through FAT10 pathway inhibition
#472COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEUROLOGICAL DISEASE
#473TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
#474Transgenic pig models of cystic fibrosis
#475TRANSGENIC PIGS LACKING ONE OR MORE CELLULAR TRANSPORT GENES
#476VITAMIN K EPOXIDE RECYCLING POLYPEPTIDE VKORC1, A THERAPEUTIC TARGET OF COUMARIN AND THEIR DERIVATIVES
#477Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity
#478Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
#479Telomerase reverse transcriptase-based therapies
#480Knockout mouse, method for screening substance for suppressing mesial temporal lobe epilepsy, and method for selecting technique for suppressing mesial temporal lobe epilepsy
#481Production of fertile XY female mice from XY mouse ES cells
#482Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
#483Method for treating arthritis using IK factor or nucleic acid encoding IK factor
#484Targeted modification of rat genome
#485MrgprX2/MrgprB2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions
#486MODELS OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND METHODS OF USE THEREOF
#487PERFORIN 2 DEFENSE AGAINST INVASIVE AND MULTIDRUG RESISTANT PATHOGENS
#488Ungulates with Genetically Modified Immune Systems
#489Method of preventing polycystic kidney disease and PKD animal model with exogenous neutrophil gelatinase-associated lipocalin
#490Preventive or therapeutic agent for kidney disease
#491NON-HUMAN ANIMALS EXPRESSING HUMANIZED CD3 COMPLEX
#492METHODS FOR TREATMENT AND PREVENTION OF TAUOPATHIES AND AMYLOID BETA AMYLOIDOSIS BY MODULATING CRF RECEPTOR SIGNALING
#493APPLICATION OF GPR45 GENE
#494Non-human animals having a humanized lymphocyte-activation gene 3
#495NANOS KNOCK-OUT THAT ABLATES GERMLINE CELLS
#496CO-ACTIVATION OF MTOR AND STAT3 PATHWAYS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION
#497Genetically modified non-human mammals and cells
#498Genetically encoded histone reporter allele constructs
#499Humanized dipeptidyl-peptidase IV (DPP4) animals
#500Method of genetically altering and producing allergy free cats
#501NORMALIZATION OF THE ENTEROHEPATIC CIRCULATION IN ANIMALS WITH A CHIMERIC HUMANIZED LIVER
#502Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission
#503Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses and applications
#504DNA methyltransferases for the treatment and prevention of arthritis
#505Method for screening gene expression in lincRNA-deficient mice or rats
#506Compositions and methods utilizing lysophosphatidylcholine scaffolds
#507Methods and compositions for the targeted modification of a mouse embryonic stem cell genome
#508Methods and compositions for mitochondrial replacement therapy
#509Mouse model of hyperuricemia
#510Progranulin (PGRN) and its derivatives for diagnosis and treatment of lysosomal storage diseases
#511Mouse λ light chain locus
#512Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors
#513Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#514Novel Brain Chemokine Samdori and Use Thereof
#515Pathogen-resistant animals having modified CD163 genes
#516Methods of treating or preventing pruritis by blocking natriuretic polypeptide B
#517SorCS1 for the treatment of obesity
#518Methods for treating diet-induced obesity by decreasing or inhibiting P2Y2 purinergic receptor expression or activity
#519Methods for treating disorders that involve immunoglobulin A
#520Genetically modified non-human animals and methods of use thereof
#521Interleukin 2 receptor gamma gene targeting vector, production of immune cell-deficient transgenic cloned mini pig having vector introduced therein, preparation method therefor and use thereof
#522Recombination activating gene 2 gene targeting vector, production of SCID-like miniature pigs by TALEN-mediated gene targeting and use thereof
#523SIGNATURES AND DETERMINANTS ASSOCIATED WITH PROSTATE CANCER PROGRESSION AND METHODS OF USE THEREOF
#524COMPOSITIONS AND METHODS FOR PRODUCING GENETICALLY MODIFIED ANIMALS
#525Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
#526Transgenic Animals
#527TRANSGENIC MOUSE MODELS FOR MC4R
#528Animal models and therapeutic molecules
#529Genetically modified non-human animals and methods relating to innate immune system response detection
#530Non-human animals having a disruption in a C9ORF72 locus
#531Compositions and methods for treating autoimmune and inflammatory diseases
#532Anti-tumor properties of Dickkopf 3b
#533Transgenic transchromosomal rodents for making human antibodies
#534ORGAN REGENERATION METHOD UTILIZING iPS CELL AND BLASTOCYST COMPLEMENTATION
#535Methods and compositions for generating a mouse
#536Humanized monoclonal antibodies from a transgenic rat
#537TRANSGENIC BIRDS THAT PRODUCE CHIMERIC HUMAN IMMUNOGLOBULINS
#538Promoter-regulated differentiation-dependent self-deleting cassette
#539GENETICALLY MODIFIED RAT MODELS FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID)
#540Transgenic chicken comprising an inactivated immunoglobulin gene
#541Genetically modified non-human animals and methods of use thereof
#542Antibody production
#543Production of fertile XY female animals from XY ES cells
#544Method of producing infertile fish and egg-producing aquatic animals and of delivering compounds into eggs and embryos
#545Multi-transgenic pigs for diabetes treatment
#546Immunocompromised ungulates
#547METHODS AND MATERIALS FOR PRODUCING TRANSGENIC ARTIODACTYLS
#548Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
#549Fumarylacetoacetate hydrolase (Fah)-deficient and immunodeficient rats and uses thereof
#550Compositions and methods for modulating neuronal excitability and motor behavior
#551Mammalian gene modification method using electroporation
#552Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch
#553Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
#554Methods and compositions for targeted genetic modification through single-step multiple targeting
#555GENETICALLY MODIFIED RAT MODELS FOR DRUG METABOLISM
#556GENETICALLY MODIFIED RAT MODELS FOR PAIN
#557Transgenic factor VII having a specific N-glycosylation and substantially homogenous isoelectric point
#558miRNA-regulated differentiation-dependent self-deleting cassette
#559Micro-RNA family that modulates fibrosis and uses thereof
#560Micro-RNA family that modulates fibrosis and uses thereof
#561Micro-RNA family that modulates fibrosis and uses thereof
#562MRAP2 KNOCKOUTS
#563Animal Models of Ataxia-Telangiectasia (A-T)
#564COMPOSITIONS AND METHODS FOR THE STUDY AND TREATMENT OF ACUTE KIDNEY INJURY
#565TAFA4 compounds and uses thereof for treating pain
#566Methods for treatment comprising an antibody that binds CD223 protein
#567Prophylactic and/or therapeutic agent for inflammatory disease, and method for screening prophylactic and/or therapeutic drug for inflammatory disease
#568Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof
#569NON HUMAN ANIMAL MODEL FOR ULCERATIVE COLITIS AND ITS MAIN COMPLICATIONS
#570TRANSGENIC NON-HUMAN ORGANISMS WITH NON-FUNCTIONAL TSPO GENES
#571METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATIONS AND METHODS OF USE
#572MULTIPLEX GENE EDITING
#573TGIF2-induced reprogramming of hepatic cells to pancreatic progenitor cells and medical uses thereof
#574SorCS1-like agent for use in the treatment of insulin resistance and diseases related thereto
#575ANIMAL MODEL RESISTANT TO HEARING LOSS
#576Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
#577Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generation
#578Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
#579Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
#580Identification of a 5-Gene Expression Signature Predicting Clinical Outcome of Patients with Brain Tumors
#581Weight loss by inhibition of gastrokine
#582Genetically modified non-human animals expressing human EPO
#583Cancer treatment and immune system regulation through FAT10 pathway inhibition
#584Fibrotic non-human animal, and use thereof
#585Low affinity FCGR deficient mice
#586Genetically edited pigs comprising a modification in the RELA gene
#587Medicament comprising activity modulator for CD300a-expressing cell associated with allergic disease, CD300a gene-deficient mouse, and use of activity modulator for CD300a-expressing cell
#588Animal model for type 2 diabetes and obesity
#589Animal models of neurological disorders
#590Double knockout (GT/CMAH-KO) pigs, organs and tissues
#591Composition and methods for the prevention and treatment of diet-induced obesity
#592METHODS AND COMPOSITIONS FOR TREATMENT OF TH2-MEDIATED AND TH17-MEDIATED DISEASES
#593Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch
#594Methods for producing a population of pancreatic beta-cells
#595Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#596Transgenic Animal
#597Mice that make heavy chain antibodies
#598Use of RET agonist molecules for haematopoietic stem cell expansion protocols and transplantation therapy and a RET agonist kit
#599Methods of treating metabolic disease
#600Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase